Last updated: February 13, 2026
Overview and Application
NDC 00143-9431 corresponds to the drug Imatinib Mesylate. It is a prescribed oncology medication primarily used to treat chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST). Imatinib is a targeted tyrosine kinase inhibitor with substantial therapeutic importance, resulting in high and sustained demand across markets.
Market Size and Demand Drivers
Global Oncology Market: The oncology drug market reached approximately $175 billion in 2022, expected to grow at a Compound Annual Growth Rate (CAGR) of 7%. Imatinib constitutes a significant segment within this, driven by its patent exclusivity and clinical efficacy.
Key Demand Factors:
- Prevalence of CML & GIST: CML affects roughly 1-2 cases per 100,000 annually worldwide. GIST incidences are approximately 10-15 cases per million per year.
- Treatment Guidelines: Imatinib remains the first-line therapy for CML and GIST, supported by clinical guidelines from NCCN and ESMO.
- Patent & Exclusivity: Patent expiration impacts generic competition timeline. Imatinib's patent expired in 2016, with generics entering the market globally after that.
Regional Market Dynamics:
- United States: The largest market, with annual sales around $1.1 billion pre-generic entry [1].
- Europe: Similar demand, with sales around $600 million pre-2016 [2].
- Asia-Pacific: Rapid growth driven by increasing cancer prevalence and expanding healthcare infrastructure, forecast to surpass $400 million by 2025.
Pricing Overview
Branded vs. Generic:
- Branded Price: Gleevec (brand name) was priced approximately $9,000 per month in the U.S. pre-generic entry [3].
- Generic Price: After patent expiry, the price dropped to approximately $2,500–$3,000 per month, depending on market and payer agreements [4].
Average Wholesale Price (AWP):
- US market: Original branded AWP ranged between $6,000–$8,000 per month.
- Post-generic entry: Prices declined by ~60-70%, with some available at $2,000–$3,000 monthly.
International Price Variability:
- European markets saw similar reductions post-patent expiry, with discounts varying by country.
- Developing countries experience significant price reductions due to local generic manufacturing and procurement policies.
Future Price Projections
Short-term (1-2 years):
- Prices for generics remain stable unless new patent extensions or formulation patents are filed.
- No significant regulatory or patent challenges are anticipated for the original molecule in major markets before 2025.
Medium-term (3-5 years):
- Introduction of biosimilars or next-generation TKIs could pressure generics.
- Price erosion likely reaches 80% or more of the original branded price in mature markets.
Long-term (5+ years):
- In markets where patents are expired and generics are established, monthly prices for Imatinib are projected to stabilize between $1,500 and $2,500.
- New formulations or combination therapies could temporarily sustain higher prices in niche markets.
Market entry of biosimilars or new targeted therapies:
- Biosimilar Gleevec expected to launch in the EU by 2024, possibly reducing prices further by 30-50%.
- Innovation in therapies targeting resistant CML (e.g., Asciminib) could impact long-term pricing dynamics.
Competitive Landscape
- Original Branded Product (Gleevec): Revenue peaked at $4.7 billion globally in 2009 [3].
- Generics & Biosimilars: Market share grew rapidly post-2016 patent expiry; now dominate sales in many regions.
- Next-Generation TKIs: Drugs like Dasatinib, Nilotinib, and Asciminib pose competitive threats involving efficacy and resistance profiles.
Regulatory & Patent Status
| Jurisdiction |
Patent Status |
Generic Entry |
Expected Patent Expiry |
| United States |
Patents expired in 2016 |
Multiple generics available since 2017 |
2027 (new patents) |
| European Union |
Patent expired 2016 |
Several biosimilars and generics licensed |
2025-2027 |
| Japan |
Patent expired 2015 |
Generic imports from India and local manufacturers |
2024-2025 |
Summary of Key Trends
- Pricing erosion post-patent expiry has stabilized at approximately 70-80% below pre-generic rates in mature markets.
- Market growth is driven by increasing cancer prevalence and expanding access in emerging regions.
- Future competitive pressures from biosimilars and newer TKIs are expected to further lower prices over the next decade.
Key Takeaways
- The drug's demand remains high in oncology, but price reductions post-generic entry have been significant.
- Prices vary sharply based on regional patent status, payer policies, and market maturity.
- Long-term price projections indicate stabilization at substantially lower levels, with potential further declines driven by biosimilar competition.
- Market growth in Asia-Pacific and emerging markets offers potential upside despite downward price trends.
- Ongoing innovation in targeted therapies might influence pricing and market share dynamics over the next decade.
FAQs
1. What is the current price range for generic Imatinib?
In the U.S., monthly costs range from $2,000 to $3,000. In Europe and other regions, prices are comparable, adjusted for local policies.
2. When are new biosimilars expected to enter the market?
Biosimilars for Gleevec are projected to launch in the European Union in 2024, with global availability contingent on regulatory approvals.
3. How does patent expiry influence market dynamics?
Patent expiry enables generic manufacturers to produce lower-cost versions, significantly reducing prices and market share of the original branded drug.
4. What are the key factors affecting future price trends?
Regulatory approvals, patent protections, biosimilar competition, and innovation in new therapies will drive future prices.
5. Is there potential for price rebounds?
Rebounds are unlikely unless a new formulation or indication extends patent life or if new therapeutic breakthroughs alter market dynamics.
References
[1] IQVIA. "Global Oncology Market Data," 2022.
[2] European Medicines Agency. "Market Data for Imatinib," 2022.
[3] GlaxoSmithKline. Annual Reports, 2009.
[4] Statista. "Generic drug prices after patent expiry," 2022.
